On Friday, Kamada Ltd. (TASE: KMDA) announced that the US Food and Drug Administration (FDA) approved for marketing the company's intravenous intravenous AAT (Alpha-1 Antitrypsin) drug for congenital respiratory diseases. The drug has the commercial name "Glassia".
Kamada estimates sales of the drug at several million dollars already this year, and that sales will total tens of millions of dollars over the next few years.
Kamada's share price jumped 7% at the opening on the TASE, but fell back to a gain of 4% by mid-morning to NIS 26.26, giving a market cap of NIS 700 million.
Published by Globes [online], Israel business news - www.globes-online.com - on July 4, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010